ETONEton Pharmaceuticals, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~28% a year FCF growth. The price demands less than its three-year revenue growth of 54% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ETON's price assumes
Today's price asks for 28% free cash flow growth a year; over the last three years Eton Pharmaceuticals, Inc. delivered 30%, less than the record.
- Free cash flow yield
- 0.98%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +28%
Growth the price implies · The price pays for +28% free cash flow growth a year for a decade; the business has delivered +30% a year over the last three.
Details›
- Free cash flow, trailing twelve months
- $15M
- Market capitalisation
- $1.50B
- 3-year revenue growth
- +54%
- 3-year free cash flow growth
- +30%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #34 of 41 by RyuScore